Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Prostate Cancer
• Age: Between 18 - 100 Years
• Gender: Male

• Other Inclusion Criteria:
  

  1) Histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma. 2) Metastatic, castration-resistant prostate cancer (mCRPC) with PSA value at screening =4 ng/mL that has progressed within 6 months prior to screening as defined in the protocol. 3) Adequate organ and bone marrow function.
  

You may not be eligible for this study if the following are true:

• 1) Has received treatment with an approved systemic therapy within 3 weeks of dosing or has not yet recovered (ie, grade =1 or baseline) from any acute toxicities. 2) Has received any previous systemic biologic therapy within 5 half-lives of first dose of study therapy and has received prior PSMA-targeting therapy. 3) Dose Expansion Only: Has had prior anti-cancer immunotherapy - Any condition that requires ongoing/continuous corticosteroid therapy (>10 mg prednisone/day or anti-inflammatory equivalent) within 1 week prior to the first dose of study therapy.